These inhibitors could be tested in other diseases that involve NGAL, such as metabolic and cardiovascular diseases or cancer, such as breast or prostate cancers, for which genetic Lcn2 inactivation and NGAL-neutralizing antibodies have proven to be beneficial. This evidence concerns the gene LCN2 and Familial prostate cancer.